A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. - Test2 - elhamkhani - TriplyDB

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

http://www.wikidata.org/entity/Q36775219

about

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems Translational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in Schizophrenia A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment.Drug models of schizophrenia nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of α7 nicotinic acetylcholine receptors.Neurology issues in schizophrenia.Neurobiological background of negative symptoms.In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia.A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys Lynx1 shifts α4β2 nicotinic receptor subunit stoichiometry by affecting assembly in the endoplasmic reticulum.The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.Investigation of cigarette smoking among male schizophrenia patients.Reliability and validity of the CogState battery Chinese language version in schizophrenia.AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis.The 4th Schizophrenia International Research Society Conference, 5-9 April 2014, Florence, Italy: a summary of topics and trends.Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data.An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.Design and Synthesis of Nicotinic Acetylcholine Receptor Antagonists and their Effect on Cognitive Impairment.Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands.Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.Identification and in vitro pharmacological characterization of a novel and selective α7 nicotinic acetylcholine receptor agonist, Br-IQ17B.α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia Cholinergic connectivity: it's implications for psychiatric disorders.Nicotinic receptors in neurodegeneration.Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.The potential role of dopamine D₃ receptor neurotransmission in cognition.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker

P2860

Q22241447-E53AF775-738C-40E5-84BB-BFB278A1B2F0 Q26765419-2D643CE4-8A82-4AC4-A74E-21280268CD5B Q26786247-9D780E15-36CD-498A-9B69-4F6C187DD151 Q26801568-9E14387E-1774-422F-A06D-656FA167589C Q27324628-1D749E1C-9D4D-4A9D-89AE-40D61BCC70A5 Q28084198-84ADA1B7-8BDB-41C0-879E-548889998F96 Q30362464-FD4F97BC-30B1-4CD2-875B-DAF66E3B8F8C Q30372351-A1D03272-AEC0-4208-A8D9-588BD36D975E Q30381001-6E9826FF-791B-42B5-B93D-D2C3629D234F Q30391389-6CF690B9-B001-4262-9520-A6074E19B3B4 Q30428422-DB09D643-A38B-4B3A-8022-03E38F048D9F Q30570721-B5681B6D-B9DE-4CC3-AB09-AAA53E7C8E35 Q30910367-56BD17DC-C46F-4CD8-958E-B1184BE9A161 Q30913824-16D93BE7-2299-4782-878A-C8F893565614 Q33605318-FF8A9EA3-BC56-49E9-9201-6F5EA2AACA0F Q33620592-F3BEA129-C502-4650-812F-BE9A0D94492E Q34186299-4AFA5A89-36C7-4785-B670-45B8978DB004 Q34467639-666BB770-DC4E-4754-A37E-596F0493ED88 Q34531316-703CD43E-F81F-4962-857F-83BE446B0ABF Q34870758-352244B6-9611-4C00-B168-585B4A50CC16 Q34879435-E12EB9C5-ABF8-4637-A12D-58CBFEEC5EAA Q34970938-F9687491-E1C4-42FE-946B-1C0AFE6D1F51 Q34984648-C5C09396-9CDD-40FE-8CEA-A93683EE5F98 Q35111465-42A1E0FD-B1C6-446D-9AA1-3B23A4D75214 Q35302795-1C14EE0F-3CD0-4235-BD87-08B8D13D16A3 Q35382798-DE55A9DB-1A02-4AE8-B803-6BD5F4053BB6 Q35450483-ED1607AA-F0FF-4FF0-8797-751602764075 Q35579197-170D402D-C6F3-4DC5-BDD2-A29D9DA80E41 Q35733853-A85F60CF-8343-4D6F-B1EF-601A678DC579 Q36213170-16E12D44-E332-45A8-AA02-CC96DEF56DB0 Q36243977-A923D15A-BAB8-4782-B1CB-89C83F0CA381 Q36287717-8968390E-F6AD-4EA5-82E9-0EE8F977CE3A Q36469995-8902FCD4-C2B3-4C82-80E0-8A96C8925BFE Q36579938-B6F62BD1-9100-4B94-86F0-B84ABB6BB0DC Q36812599-A42DE27C-A59B-4B23-B9B5-582DA4A20DF4 Q36828916-D7C2AD3B-7BDF-44F8-B74A-F4DBB4530FAD Q36935148-491CC461-B457-4F57-964C-25E30EA70BF0 Q37067455-95E6B47A-354B-42ED-9B2C-DBCF2C0B76DB Q37106827-E8EF6668-BA03-4947-ABE2-1F51BD0E0993 Q37258840-017C3D98-3232-4823-ABEF-B587B9772C34

P2860

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

http://www.wikidata.org/entity/Q36775219

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

A randomized exploratory trial ...... enhancement in schizophrenia.

@ast

A randomized exploratory trial ...... enhancement in schizophrenia.

@en

type

label

A randomized exploratory trial ...... enhancement in schizophrenia.

@ast

A randomized exploratory trial ...... enhancement in schizophrenia.

@en

prefLabel

A randomized exploratory trial ...... enhancement in schizophrenia.

@ast

A randomized exploratory trial ...... enhancement in schizophrenia.

@en

P1433

Q36775219-4BE4C589-BCBD-4F16-89E7-6C5B05013D11

P1476

Q36775219-4493CC1D-F609-4427-BB4F-558961C469E3

P2093

Q36775219-23AC9EEC-55F0-4FC5-AF80-E502D4445721

Q36775219-2DD2DB81-3ABE-4E51-B8A6-E4CF5CE89B40

Q36775219-47DAE0E4-262D-45DB-B165-BF60D8B49946

Q36775219-8497FF9A-EB4C-4DEF-9D95-347AE9D4A61F

Q36775219-8E99DAD3-2C23-41AD-8FB9-D22ED1A57679

Q36775219-937ADE78-ACAA-43EF-9BB2-E97448164A29

Q36775219-C2E6C104-DA16-4ACD-98A9-720702D783F4

P2860

Q36775219-022C3BB8-EF0B-4BFA-BD44-DEF6CFAEE615

Q36775219-0A948CBA-A80C-4997-92AE-98357148E85F

Q36775219-15169167-2058-4D35-BC64-F474B266795E

Q36775219-1FE1C2B2-7FEC-42F9-BCEF-A3235E494DD4

Q36775219-20BEB5C7-FD0C-4094-90A8-48BD3F48D1EE

Q36775219-268CAE0D-3EAA-4F1C-A955-185A4156D243

Q36775219-31E1227A-168E-4195-AEDC-EE29808159EE

Q36775219-326537E5-9B21-417F-B667-4C37B10185BE

Q36775219-341E4DCC-AB76-4DC4-B079-839DAFE8CE7F

Q36775219-3FBE5C91-7EDF-40EA-8499-BD6C8715845A

P2888

Q36775219-D6495B80-8012-4540-806A-C182F609E2BE

P304

Q36775219-88A9093C-2296-4058-BBB7-09043B13C7C0

P31

Q36775219-5DF85B54-86B1-497E-85BC-A1549C52EA24

P356

Q36775219-1B897A0D-94B3-4057-93F0-69A641D788E3

P407

Q36775219-5BDC0AEB-71E9-45BB-BFE3-354602915F7B

P433

Q36775219-F744AD36-0120-4196-B062-77726EE7D561

P478

Q36775219-38D0CFFC-7B82-49C5-B3CA-37E7B7ECA710

P50

Q36775219-F6020341-67EC-41E4-A16A-89986D046C71

P577

Q36775219-1D10C677-17F1-4B7D-8490-78FF2BAD16B7

P5875

Q36775219-23B1D416-075B-4900-9AC4-09304A229BC1

P6179

Q36775219-15B6FB47-AC55-4875-8146-04A0270DFCA6

P698

Q36775219-B42B186C-FA9A-4637-A657-E35EE16B55EF

P921

Q36775219-29B96B78-7FEC-42F9-B888-4808B6DA3AEC

P932

Q36775219-D4D26063-695D-40E6-8A15-D8C6E3EC40DD

P356

P1433

Neuropsychopharmacology

P1476

A randomized exploratory trial ...... enhancement in schizophrenia.

@en

P2093

Anthony C Segreti

http://www.w3.org/2001/XMLSchema#string

David A Hosford

http://www.w3.org/2001/XMLSchema#string

Frances Seoane

http://www.w3.org/2001/XMLSchema#string

Geoffrey Dunbar

http://www.w3.org/2001/XMLSchema#string

Jessica S Beaver

http://www.w3.org/2001/XMLSchema#string

Naihua Duan

http://www.w3.org/2001/XMLSchema#string

Ragy R Girgis

http://www.w3.org/2001/XMLSchema#string

P2860

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

Prevalence of smoking among psychiatric outpatients

TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.

Molecular targets for treating cognitive dysfunction in schizophrenia.

Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers.

Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia.

Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution.

Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

P2888

P304

968-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2012.259

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey Lieberman

P577

2012-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234098727

http://www.w3.org/2001/XMLSchema#string

P6179

1042733593

http://www.w3.org/2001/XMLSchema#string

P698

23303043

http://www.w3.org/2001/XMLSchema#string

P921

P932

3629385

http://www.w3.org/2001/XMLSchema#string